Ann Rheum Dis: Bimekizumab Double Middle and Lemynesin-17A and 17F Therapeutic Aggressive Syllitis

Bimekizumab selective lymes (IL)-17A and IL-17FThe efficacy and safety of bimekizumab in a phase IIb dose-range study of active syllable scoliosis (AS) are reported hererandomly divided adult AS patients (in line with the revised New York standard) into 1:1:1:1:1 ratios of 1:1:1,1 per 4 weeks bimekizumab 16mg, 64 mg, 160mg, 320mg, or placebo groups for a total of 12 weeks (double blindness)At the 12th week, patients in the bimekizumab 16mg, 64mg or placebo group were re-randomized at 1:1 to bimekizumab 160mg or 320mg every 4 weeks for 48weeksOther patients continue their initial dose (dose blindness)The main endpoint is the 12th week of the International Association for the Assessment of Spinal Arthritis (ASAS) 40 Responses (Missing Data Using No Response Interpolation (NRI)303 patients were randomly grouped: bimekizumab 16mg (n-61), 64mg (n-61), 160mg (n-60), 320mg (n-61) or placebo (n-60)At week 12, the number of patients treated with ASAS40 was significantly higher than in the placebo group (NRI:29.5%-46.7% vs 13.3% ;p average 0.05; OR vs placebo 2.6-5.5 (95% CI 1.0-12.9)Significant dose-response (p 0.001) was observedThe primary endpoint is supported by all minor therapeutic outcomesIn week 48, 58.6% and 62.3% of patients treated with bimekizumab 160 and 320 mg met ASAS40 (NRI) for the entire study period; During double blindness, 26/60 patients in the placebo group (43.3%) and 92/243 patients in the bimekizumab group (37.9%) had adverse events requiring treatmentBimekizumab can quickly and continuously improve key outcome indicators for active AS patientsCompared with previous studies, there were no unexpected safety findings